cjc-1295 ipamorelin clinical trial body composition / Data: What the… CJC-1295/Ipamorelin Peptide Therapy | TRTMD
Description
A post hoc analysis revealed difficulties in deciding the timing for discontinuation or suspension of oxaliplatin in patients with grade 2 OIPN, because physician likely underestimated OIPN via the Common Terminology Criteria for Adverse Events (CTCAE) and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) in patients with mCRC during early treatment (Miura et al., 2021)
Ipamorelin is a type of peptide therapy known as a growth hormone secretagogue
Dong, A
Sood N, Garg R
Haloo semuaa
